HJ445A
HJ445A is a potent MYOF inhibitor and binds to the MYOF-C2D domain with a KD of 0.17 μM. HJ445A potently repressed the proliferation of gastric cancer cells with IC50 values of 0.16 and 0.14 μM in MGC803 and MKN45, respectively. HJ445A demonstrates superior antitumor efficacy in vivo and can be used for cancer research[1].
Product Specifications
CAS Number
[3032441-59-8]
UNSPSC
12352005
Target
Others
Type
Reference compound
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hj445a.html
Concentration
10mM
Purity
98.31
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CCC1=NN(C2=CC=CC(C(NCCCCN3N=CC=N3)=O)=C2)C(C4=CC=C(C=C4)OC)=N1
Molecular Formula
C24H27N7O2
Molecular Weight
445.52
References & Citations
[1]Haijun Gu, et al. Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer. J Med Chem. 2023 Dec 6.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6140025-01 0.1 mL
ACVR1B (Activin A Receptor, Type IB, ACTRIB, ACVRLK4, ALK4, SKR2) APC
Ask
View Details MBS6140025-02 5x 0.1 mL
ACVR1B (Activin A Receptor, Type IB, ACTRIB, ACVRLK4, ALK4, SKR2) APC
Ask
View Details 172139-AF-ML405 100 µL
PGP9.5 (Gracile Axonal Dystrophy, Neuron Cytoplasmic Protein 9.5, Park5, Parkinson Disease 5, PGP95, Protein Gene Product 9.5, Ubiquitin Carboxyl-terminal Esterase L1, Ubiquitin Carboxyl-terminal Hydrolase Isozyme L1, Ubiquitin Thioesterase L1, Ubiquitin Thiolesterase L1, UchL1) (BSA & Azide Free) (MaxLight 405) discontinued
Ask
View Details 